AstraZeneca's Fasenra: Approval for asthma may initiate COPD approval [Yahoo! Finance]
AstraZeneca PLC - American Depositary Shares (AZN)
Last astrazeneca plc - american depositary shares earnings: 2/5 04:00 pm
Check Earnings Report
US:NYSE Investor Relations:
astrazeneca.com/investor-relations.html
Company Research
Source: Yahoo! Finance
Fasenra is a monoclonal antibody that inhibits the alpha subunit of the interleukin-5 receptor found on eosinophils and attracts natural killer cells to induce the near-complete depletion of eosinophils via programmed cell death. It was first approved in 2017 in the US as an add-on maintenance therapy for the treatment of severe eosinophilic asthma in patients aged 12 years and older and is currently undergoing a Phase III clinical trial for chronic obstructive pulmonary disease (COPD). According to leading data and analytics company GlobalData 's Sales and Forecast database, total sales for Fasenra are set to reach $2.0bn globally by 2029. COPD is a heterogeneous, progressive lung disease characterised by chronic symptoms, including dyspnea, cough, sputum production, and/or exacerbations (GOLD, 2022). Therapies for COPD have been in development for decades to reduce exacerbations and manage the symptom load of the disease, with biologics dominating the late-stage COPD pipeli
Show less
Read more
Impact Snapshot
Event Time:
AZN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AZN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AZN alerts
High impacting AstraZeneca PLC - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
AZN
News
- AstraZeneca's COVID-19 Prevention Therapy Cuts Risk Of Infection In Patients With Weaker Immunity, Data Shows [Yahoo! Finance]Yahoo! Finance
- AstraZeneca COVID therapy succeeds in late-stage study for the vulnerable [Seeking Alpha]Seeking Alpha
- Zephyr AI Announces the Appointment of John Applegate as its CFO [Yahoo! Finance]Yahoo! Finance
- Silence Therapeutics Reports First Quarter 2024 Results and Highlights Pipeline Progress [Yahoo! Finance]Yahoo! Finance
- Venatorx Pharmaceuticals Announces Changes to Executive Leadership [Yahoo! Finance]Yahoo! Finance
AZN
Sec Filings
- 5/16/24 - Form 6-K
- 5/15/24 - Form 6-K
- 5/7/24 - Form 6-K
- AZN's page on the SEC website